Regional Virus Laboratory/Pathogen Sequencing
LG.031 Institute of Pathology
Belfast Health and Social Care Trust
Grosvenor Road, Belfast, BT12 6BA

Belfast Health and Social Care Trust
caring supporting improving together

# HIV Drug Resistance Report

## Patient information

Name: **H,T**

Sex: **F**

DOB/Age: **31/12/1985**

H&C number/SP Number: **9903393725**

Lab no: **V33024431**

## Sequence summary

Sequence includes HIV1 IN, codons 1-288 missing: None

**HIV subtype: HIV subtype cannot be determined from integrase alone**

| Drug | Generic Name | Type | Resistance Call |
|---|---|---|---|
| BIC | bictegravir | INSTI | Susceptible |
| CAB | cabotegravir | INSTI | Susceptible |
| DTG | dolutegravir | INSTI | Susceptible |
| EVG | elvitegravir | INSTI | Susceptible |
| RAL | raltegravir | INSTI | Susceptible |

Date of specimen collection: 14/05/2022 Specimen type: EDTA Blood Date received: 05/05/2023

Regional Virus Laboratory/Pathogen Sequencing
LG.031 Institute of Pathology
Belfast Health and Social Care Trust
Grosvenor Road, Belfast, BT12 6BA

Belfast Health and Social Care Trust
caring supporting improving together

## Significant mutations

**Integrase inhibitor mutations**: No mutations of this type were detected

## Other mutations

**IN other mutations:** E11D, S24N, S39M, I72V, L101I, S119P, I135V, Q177L, V201I, L234I, S283G

## Significant comments

### INT comments:

No comment

## Other comments

### IN comments:

No comment

## Definitions for drug susceptibility

"Susceptible" indicates no evidence of reduced ARV susceptibility compared with a wild-type virus.
"Potential low-level resistance" indicates that the sequence may contain mutations indicating previous ARV exposure or may contain mutation that are associated with drug resistance only when they occur with additional mutations.
"Low-level resistance" indicates that there that the virus encoded by the submitted sequence may have reduced in vitro ARV susceptibility or that patients harboring viruses with the submitted mutations may have a suboptimal virological response to treatment with the ARV. "Intermediate resistance" indicates a high likelihood that a drug's activity will be reduced but that the drug will likely retain significant remaining antiviral activity.
High-level resistance" indicates that the predicted level of resistance is similar to those observed in viruses with the highest levels of in vitro drug resistance or that clinical data exist demonstrating that patients infected with viruses having such mutations usually have little or no virological response to treatment with the ARV. Further information is available here.

---

Date and time created: 09/10/2023,09:43